Skip to content
Twist Bioscience logo — Synthetic DNA for Health & Sustainability

Twist Bioscience

Synthetic DNA for Health & Sustainability

Founded 2013 United States South San Francisco, United States 1315 employees IPO Total: $943.10M Biotechnology, Health Care +1

General Information

Company Name Twist Bioscience
Founded Year 2013
Location United States South San Francisco, United States
Employees 1315
Industries Biotechnology, Health Care, Life Sciences
Funding Stage IPO
Business Model B2B, D2C, SaaS
Revenue Model Product Sales, Service Fee, Licensing
Offices as of Nov 2026
South San Francisco, United States San Francisco, United States Tel Aviv, Israel Carlsbad, United States Wilsonville, United States Quincy, United States

BounceWatch is an independent company data service, not affiliated with Twist Bioscience. To contact Twist Bioscience, visit twistbioscience.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Twist Bioscience compare?

A PDF of Twist Bioscience and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Twist Bioscience soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Award Received Nov 20, 2026

Twist Bioscience was named one of TIME’s America’s Top Manufacturers of 2027.

Major Customer Win Nov 19, 2026

Twist Bioscience supplied synthetic DNA for teams participating in the iGEM 2026 competition.

In The News Nov 14, 2026

Featured on CoinMarketCap: Twist Bioscience Corporation Tokenized Stock (Ondo) price today, TWSTon to USD l...

In The News Nov 14, 2026

Featured on Simply Wall St: Twist Bioscience (TWST) Stock May Look Rich As Sales Face A High Bar

In The News Nov 13, 2026

Featured on Investing.com: TD Cowen cuts Twist Bioscience stock price target on execution concerns

New Partnership Nov 13, 2026

Twist Bioscience partners with ABreal for an upcoming webinar on AI antibody design.

+3 more signals in last 30 days

AI Insight

Bounce Watch AI
2 weeks ago

Twist Bioscience exhibits robust operational momentum, reporting 14 consecutive quarters of growth, which underscores sustained demand for its synthetic DNA platforms. This consistent expansion is supported by strategic customer wins, such as supplying control material to public health laboratories for rapid assay development, validating the critical utility of their offerings. The company continues to secure significant post-IPO equity financing, indicating strong investor confidence and solidifying its financial position for future strategic initiatives.

Signal Types
Growth Customer Acquisition Funding Market Performance
Strategic Labels
Sustained Growth Market Validation Capital Access
Next Move: Expansion
·
Impact: 9/10
·
Ideal For: Public Equity Investors — Biotechnology, Life Sciences Growth Funds

About Twist Bioscience

Twist Bioscience, a leading force in synthetic biology, is based in South San Francisco, California. Founded in 2013, the company's mission—a resonant "Synthetic DNA for Health & Sustainability"—is to empower life science research across diverse fields such as medicine, agriculture, and industrial chemicals.

At its core, Twist Bioscience leverages a proprietary silicon-based manufacturing process to deliver high-precision and high-throughput synthetic DNA. This unparalleled capability allows researchers to drive forward sustainability and health innovations by enhancing the quality and speed of DNA synthesis and sequencing.

The company's value proposition is underscored by a recent $250.00M Post Ipo Equity investment dated 01 August 2026. This capital infusion positions Twist Bioscience robustly in the Biotechnology and Life Sciences sector as it continues to overcome existing efficiency barriers. Without publicly disclosed investors for the latest funding, the company maintains a strategic ambiguity in its investment relations.

Business keywords: Synthetic Biology, DNA Synthesis, Gene Synthesis, CRISPR, Drug Discovery, Next Gen Sequencing, DNA Data Storage, Variant Libraries, DNA Sequencing, Exome Sequencing, Target Enrichment, Oligonucleotides, Life Sciences, Biopharma Services

Services & Products

Gene Synthesis
Antibody Production and Characterization
Library Preparation Solutions
Variant Library Development
DNA Synthesis on Silicon Platform

Target Customers

Biotechnology Companies Cancer Researchers Pharmaceutical Companies Agricultural Biotechnology Firms Infectious Disease Research Labs Genomic Research Institutions AI Drug Discovery Researchers

Funding Rounds & Investors (14)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $250.00M -
01 Aug 2026
Post-IPO Equity Undisclosed 1
Maxi Investments
01 May 2026
Post-IPO Equity $250.00M -
01 Feb 2022
Post-IPO Equity $50.00M -
01 Jan 2020
IPO $70.00M -
01 Oct 2018
IPO $70.00M -
01 Oct 2018
Late VC $50.00M -
01 Apr 2018
Series E $27.00M 4
Biomatics Capital Partners, 3W Partners +2
01 Jun 2017
Series D $33.00M 2
Asset Management Ventures, Dentsu Ventures
01 Mar 2017
Series D $61.00M 10
Asset Management Ventures, Arch Venture Partners +8
01 Jan 2016

View All 14 Funding Rounds

Twist Bioscience Alternatives & Competitors

View All Alternatives
Twist Bioscience vs

Honoring the Science of Life

56 employees
Biotechnology, Life Sciences
Twist Bioscience vs
Synbio Technologies
Synbio Technologies United States

Changing the world, one sequence at a time.

25 employees
Biotechnology, Health Care
Twist Bioscience vs
Camena Bioscience
Camena Bioscience United Kingdom

Unlocking access to genes with unparalleled accuracy

Series A
23 employees
Biotechnology, Health Care

FAQ About Twist Bioscience

Synthetic DNA for Health & Sustainability
Twist Bioscience was founded in 2013.
Twist Bioscience is headquartered in South San Francisco, United States. As of Nov 2026, it also has offices in San Francisco, United States, Tel Aviv, Israel, Carlsbad, United States, Wilsonville, United States and Quincy, United States.
Twist Bioscience operates in Biotechnology, Health Care and Life Sciences. Its work centres on Synthetic Biology, DNA Synthesis, Gene Synthesis and CRISPR. Its customers include Biotechnology Companies, Cancer Researchers and Pharmaceutical Companies.
Twist Bioscience has a B2B, D2C and SaaS business model. Its revenue comes from Product Sales, Service Fee and Licensing.
Twist Bioscience has approximately 1315 employees.
Twist Bioscience has completed 14 funding rounds, raising a total of $943.10M. The latest funding stage is IPO.
Twist Bioscience offers: Gene Synthesis, Antibody Production and Characterization, Library Preparation Solutions, Variant Library Development, DNA Synthesis on Silicon Platform.
Top alternatives and competitors to Twist Bioscience include Eurofins Genomics Americas, Synbio Technologies, Camena Bioscience, Evonetix Ltd, Molecular Assemblies, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Twist Bioscience and Eurofins Genomics Americas are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Twist Bioscience, https://www.bouncewatch.com/company/twist-bioscience, updated 20 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout